- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cardiac Ultrasound Update: FDA Clears Software with 45 Automated Parameters for Echocardiographic Analysis
Strain imaging analysis is one of the automated parameters included in the newly FDA-cleared Us2.v2 software for adjunctive review of echocardiographic images.
In what may provide a boost for streamlining cardiac ultrasound workflows, the Food and Drug Administration (FDA) has granted 510(k) clearance for the Us2.v2 software (Us2.ai), which reportedly provides 45 automated parameters for adjunctive assessment of echocardiographic images.
Key aspects of the Us2.v2 software include strain imaging assessment, regional strain analysis, aortic stenosis measurement as well as analysis of left and right atrial and ventricular linear dimensions, according to Us2.ai.
The newly FDA-cleared Us2.v2 software reportedly provides 45 automated parameters for adjunctive assessment of echocardiographic images. (Image courtesy of Us2.ai.)
Emphasizing that the software’s real-time automated capabilities reduce the variability that can occur with human assessment, Us2.ai said the Us2.v2 software also enhances workflow with explainable artificial intelligence (AI) output and streamlined reporting.
“By offering advanced capabilities that significantly enhance both precision and efficiency of echocardiographic analysis, this innovation dramatically reduces analysis time thereby speeding up clinical workflow. This is particularly helpful in clinical states that require additional imaging parameters such as strain, or are challenged by variability in interpretation such as aortic stenosis, said Madhav Swaminathan, M.D., a past president of the American Society of Echocardiography (ASE) and an associate professor of anesthesiology at Duke University Medical Center in Durham, N.C.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
